Moderna, Inc Shares Continue to Rise After a Possible Coronations Vaccine Announcement

Written by Danny Abramov

et|icon_calendar|

February 26, 2020

et|icon_grid-3×3|

Moderna, Inc., (NASDAQ: MRNA) shares continue to rise as the Coronavirus continues to spread globally. Shares of the Company jumped another 20% Wednesday and have crossed the $28 a share mark.

Moderna is a a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients. Earlier this week the Company announced that it has released the first batch of mRNA-1273, the Company’s vaccine against the novel coronavirus, for human use. Vials of mRNA-1273 have been shipped to the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH) to be used in the planned Phase 1 study in the U.S.

mRNA-1273 is an mRNA vaccine against the novel coronavirus encoding for a prefusion stabilized form of the Spike (S) protein, which was selected by Moderna in collaboration with investigators at the NIAID Vaccine Research Center (VRC). Manufacture of this batch was funded by the Coalition for Epidemic Preparedness Innovations (CEPI).

“I want to thank the entire Moderna team for their extraordinary effort in responding to this global health emergency with record speed. The collaboration across Moderna, with NIAID, and with CEPI has allowed us to deliver a clinical batch in 42 days from sequence identification,” said Juan Andres, Chief Technical Operations and Quality Officer at Moderna. “This would not have been possible without our Norwood manufacturing site, which uses leading-edge technology to enable flexible operations and ensure high quality standards are met for clinical-grade material.”

 

The Company’s manufacturing plant in Norwood, MA manufactures Moderna’s portfolio of mRNA development candidates, including vaccines and therapeutics. To date, the Company has produced and released more than 100 batches from its Norwood site for human clinical trials. mRNA-1273 is part of the Company’s core prophylactic vaccines modality, which has had six positive Phase 1 clinical readouts across six different vaccines over the past four years.

Stock price

DAY LOW/HIGH

52 week low/high

Comparables

Related Articles

Boeing Profits Slide in First Quarter as Pandemic Weighs

Boeing Profits Slide in First Quarter as Pandemic Weighs

The Boeing Company (NYSE: BA) stock jumped more than 8 percent Wednesday after it has reported first-quarter financials. The major manufacturer of commercial jetliners, military aircraft, satellites, missile defense, human space flight and launch...

Comments

Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments
0 0 votes
Article Rating
Shares
Share This